Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: DaveAu who wrote (1749)	5/6/1999 10:27:00 PM
From: William Whitehead Jr.	Read Replies (1) \| Respond to of 14101

Interesting how similar both Dimethaid and HYAL are. Booth were pursuing a similar delivery mechanism. At a pivotal point in the road each choose a different path to follow and as they say the rest is history. Agreed Bimoira is at the earliest 18 months from FDA for Theratope. But on the subject on Biomira do you know the significance of May 15-17? I like Dimethaid - very impressed with the way company conducts their affairs - remember calling Peter on a very simple matter, 20 minutes latter he was still discussing the merits of the delivery mechanism and some of the broader implications. Whitey,